Caroline Seymour

Key Takeaways FDA authorized Dato-DXd for unresectable/metastatic TNBC in adults who are not PD-1/PD-L1 inhibitor candidates, establishing a first-line TROP2-directed ADC option in this subset. TROPION-Breast02 demonstrated OS improvement over chemotherapy (HR 0.79; median 23.7 vs 18.7 months; P=.0290), meeting statistical significance with clinically meaningful separation. Blinded independent central review showed substantial PFS gain (HR 0.57; median 10.8 vs 5.6 months; P<.0001), consistent with reduced progression or death risk. Objective response rate favored Dato-DXd (64% vs 30%), reinforcing higher antitumor activity than standard single-agent chemotherapy in metastatic TNBC. No new safety signals were reported, and ADC-associated toxicity profiles may be preferable to conventional chemotherapy, enabling alternative sequencing after prior multi-agent chemo-immunotherapy. SHOW MORE

Frontline darovasertib plus crizotinib improved PFS vs investigator’s choice of therapy in patients with HLA-A*02:01–negative metastatic uveal melanoma.

Findings from the OptimUM-02 trial may support a new potential therapeutic standard for patients with HLA-A*02:01–negative metastatic uveal melanoma.

Giredestrant plus palbociclib improved PFS numerically just shy of 5 months in the persevERA trial, but was deemed negative due to lack of statistical significance.

D. Ross Camidge, MD, PhD, reflects on his journey from a gap year at McDonald’s to directing the lung cancer program where he is now a patient.

Experts recap of the most pivotal lung cancer data to surface at the 2026 ASCO Annual Meeting.

Key Takeaways Primary OS end point was missed; HRs were 1.19 for lurbinectedin monotherapy and 0.90 for lurbinectedin–irinotecan versus topotecan/irinotecan. Control arm achieved median OS 10.7 months, comparable to 10.9 months with combination and exceeding 8.7 months with monotherapy. Subgroup analysis suggested CNS metastases adversely affected lurbinectedin monotherapy (HR 1.79), whereas the combination showed no clear advantage over control in CNS-positive or -negative cohorts. Treatment-related AEs were frequent; grade ≥3 events occurred in 35.0% with monotherapy, 62.6% with combination, and 64.4% with investigator's choice, without new signals. SHOW MORE

ASCO 2026 highlights show dostarlimab may deliver curative potential in dMMR endometrial cancer, while novel ADCs and fasting reshape ovarian care.